CN Energy Group Provides Preliminary Unaudited Financial Information for the First Three Months of Fiscal Year 2024 and Announces an Operations Update

In This Article:

Preliminary revenue for the first three months of fiscal year 2024 is approximately equal to revenue for the first six months of fiscal year 2023

Committed to continually improve operations and cost structure, combined with a focus on product optimization and innovative commercial strategies that leverage the growth potential of the product portfolio, to expand margins, reduce losses and return to profitability

LISHUI, China, Feb. 26, 2024 /PRNewswire/ -- CN Energy Group. Inc. (Nasdaq: CNEY) (the "Company" or "CN Energy Group"), a high-tech enterprise specializing in cogeneration of high-quality wood-activated carbon and clean energy, today announced certain preliminary financial information for the first three months of fiscal year 2024 , as well as an update on operations.

With a robust market and increasing end customer demand for our high-quality recyclable activated carbon and renewable energy, CN Energy Group anticipates the following results for its first three months of fiscal year 2024.




Expected Range 

Revenue                                                      



$21.0M to $22.0M

Net income (loss)                                                                    



$(1.0M) to (0.8M)

Steven Berman, President and CEO of CN Energy Group, commented "Building on the momentum established in fiscal year 2023, the Company's preliminary results demonstrate that we are off to a healthy start in fiscal year 2024. There is exciting work underway, and we expect to build on our accelerating momentum and profitable growth strategy in fiscal year 2024. We are seeing revenue growth as demand increases for our wood-based activated carbon. We are currently preparing for the expansion of our products into the U.S. market for the first time in company history. We are engaged in discussions with several U.S.-based environmental companies as well as pharmaceutical manufacturers."

Berman added, "We will continue to review and diligently work towards reducing the cost of goods sold to improve our margins and increase our net income for the current fiscal year. We plan to continue to invest in our marketing strategy, sales initiatives, customer and supplier relationship management, and in our commitment to the research and development of our products. Additionally, we are looking at acquisition opportunities of accretive businesses to expand our product portfolio and leverage best-in-breed cost reduction strategies."